Mitochondrial Drug Elamipretide Restores Egg Quality and Fertility in Aging Females

Female fertility declines sharply with age, primarily due to deteriorating egg quality linked to mitochondrial dysfunction. This study demonstrates that elamipretide—a small peptide designed to stabilize mitochondrial membranes and improve energy production—can reverse this decline in animal models. The treatment improved multiple markers of oocyte health and restored fertility during reproductive aging. Elamipretide works by targeting cardiolipin, a crucial lipid in mitochondrial membranes, helping maintain proper mitochondrial structure and function. While this research was conducted in animals, the findings are particularly relevant because mitochondrial dysfunction is a well-established hallmark of aging across species, including humans. The drug has already been tested in human clinical trials for other mitochondrial diseases, suggesting a clearer path to translation than entirely novel compounds. For women facing age-related infertility, this represents a potentially groundbreaking approach beyond current assisted reproduction techniques. However, human studies specifically examining fertility outcomes are needed before we can assess real-world efficacy and safety for reproductive applications.